PT  - JOURNAL ARTICLE
AU  - Ana Babus
AU  - Sanmay Das
AU  - SangMok Lee
TI  - The Optimal Allocation of Covid-19 Vaccines
AID  - 10.1101/2020.07.22.20160143
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.22.20160143
4099  - http://medrxiv.org/content/early/2020/07/24/2020.07.22.20160143.short
4100  - http://medrxiv.org/content/early/2020/07/24/2020.07.22.20160143.full
AB  - Covid-19 vaccine prioritization is key if the initial supply of the vaccine is limited. A reasonable policy will surely prioritize populations facing high risk of severe illness in high-exposure occupations. The challenge is deciding between high-risk populations in low-exposure occupations and those that are young and healthy but work in high-exposure occupations. We estimate occupation-based infection risks and use age-based infection fatality rates in a model to assign priorities over populations with different occupations and ages. Among others, we find that 50 year-old food-processing workers and 60 year-old financial advisors are equally prioritized. Our model suggests a vaccine distribution that emphasizes age-based mortality risk more than occupation-based exposure risk. Designating some occupations as essential does not affect the optimal vaccine allocation, unless a stay-at-home order is also in effect. Even with vaccines allocated optimally, 1.37% of the employed workforce is still expected to be infected with the virus until the vaccine becomes widely available, provided the vaccine is 50% effective and assuming a supply of 60mil doses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is public and available through U.K. ONS or U.S. Census Bureau.